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Abstract
Backgrounds: There have been conflicting reports about serum golgi protein 73 (GP73) as one of the most
promising serum markers for the diagnosis of hepatocellular carcinoma (HCC). This study was to make a systematic
review about the diagnostic accuracy of serum GP73 versus alpha-fetoprotein (AFP) for HCC.
Methods: After a systematic review of related studies, sensitivity, specificity and other measures about the accuracy
of serum GP73 and AFP in the diagnosis of HCC were pooled using random-effects models. Summary receiver
operating characteristic curve analysis was used to summarize the overall test performance.
Results: Eight studies were included in our meta-analysis. The summary estimates for serum GP73 and AFP in
diagnosing HCC in the studies included were as follows: sensitivity, 76% (95% confidence interval (CI) 51-91%) vs.
70% (47-86%); specificity, 86% (95%CI 65-95%) vs. 89% (69-96%); diagnostic odds ratio (DOR), 18.59 (95%CI 5.33-
64.91) vs. 18.00(9.41-34.46); and area under sROC, 0.88 (95%CI 0.77-0.99) vs. 0.86 (95%CI 0.84-0.87).
Conclusions: The current evidence indicates that serum GP73 has a comparable accuracy to AFP for the diagnosis
of HCC, while the value of serum GP73 in combination with AFP for HCC detection deserves further investigation.
Background
Hepatocellular carcinoma (HCC) is the third leading
cause of cancer-related death worldwide. There were esti-
mated 748,000 new cases of liver cancer worldwide in
2008, causing 696,000 deaths [1]. As most patients with
HCC are diagnosed at an advanced stage with underlying
liver dysfunction [2], the mortality rate of HCC is similar
to the incidence rate. Early detection of HCC is therefore
extremely important in improving the survival of
patients. Alpha-fetoprotein (AFP), together with hepatic
ultrasonography, is the most common marker used in
clinical practice to detect HCC in cirrhotic patients, and
has been considered the gold-standard serum marker for
screening patients at high risk for HCC, as well as for the
diagnosis and monitoring of responses to HCC treatment
for over 40 years. But the clinical value of AFP is chal-
lenged in recent years due to low sensitivity and specifi-
city [3-5]. In addition, AFP levels greater than 500 ng/ml
are correlated with the tumor size: 80% of small HCC
show no increase of AFP concentration [6]. Some
patients with cirrhosis and/or hepatic inflammation
could have an elevated level of AFP without the presence
of tumors. Therefore, serum markers with better diag-
nostic accuracy are needed for HCC.
Golgi protein 73 (GP73, also known as Golph2), is a
resident Golgi-specific membrane protein expressed by
biliary epithelial cells in normal liver, and its expression is
increased markedly in chronic liver diseases, especially in
HCC cells [7]. There have been studies reporting the use
of serum GP73 as a serum marker for HCC, but the
results are heterogeneous and even conflicting. The objec-
tive of the present review was to synthesize and analyze
the results from systematic selection of research papers
that evaluated the diagnostic accuracy of serum GP73 by
directly comparing it with AFP for the diagnosis of HCC.
Methods
Inclusion and exclusion criteria
Eligible studies were those original research articles that
directly compared the diagnostic accuracy of GP73 test
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assigned patients to one of the tests using blood as the
only sample type. Studies that evaluated serum GP73 or
AFP levels by messenger RNA, DNA or DNA poly-
morphisms, or those without providing the sensitivity or
specificity of GP73 or AFP were excluded.
Studies published in English and Chinese were
included. Abstracts, letters, editorials and expert opi-
nions, reviews without original data, case reports and
studies lacking control groups were also excluded. No
restriction was set on the year of publication.
Identification of studies
A comprehensive systematic literature review of original
researches studying the diagnostic accuracy of GP73 was
performed searching the following electronic databases
through May 2011: PUBMED, EMBASE, Chinese BioMe-
dical Literature Database (CBM), Cochrane Database of
Systematic Reviews, Cochrane Central Register of Con-
trolled Trials, Database of Abstracts of Reviews of Effect
(DARE), Health Technology Assessment Database and
NHS Economic Evaluation Database (NHS-EED). In addi-
tion, references from included articles and relevant pub-
lished reports were hand searched. No restriction was set
on the language, study design, year of publication and
publishes status. Subject headings and keywords used in
the search process included the following: (1) GP73: GP73,
golgi protein 73, golgi phosphoprotein 2, golgi membrane
protein 1; and (2) HCC: HCC, hepatocellular carcinoma,
liver cell carcinoma, hepatic cell carcinoma. The PUBMED
search strategy was shown in Additional file 1. We did not
use keywords or indexing terms for diagnostic test accu-
racy since they might miss relevant studies.
Study selection
All the studies were reviewed by two reviewers (Zhou Y
and Ying J) independently based on titles and abstracts,
and then the full texts of potentially eligible studies
were retrieved for further assessment. Disagreements
between the reviewers were resolved by consensus. The
authors would be contacted for further study details
when necessary.
When the same author reported results obtained from
the same patient population in several publications, only
the most recent or the most complete report was
included in the analysis to avoid overlap between cohorts.
Data extraction
The following data were extracted from the included
studies by two reviewers (Zhou Y and Yin X) indepen-
dently: authors, year of publication, journal, study
design, number of patients, reference test, assay type of
the markers, cutoff values and raw data for the analysis
of sensitivity and specificity (the number of true positive,
false negative, true negative and false positive results) for
comparison of patients diagnosed with HCC vs. control.
Any disagreements were resolved through consultation
with the third reviewer (Zhang BH).
Assessment of methodological quality
The quality of each study was assessed according to the
QUADAS (Quality Assessment of studies of Diagnostic
Accuracy included in Systematic reviews) checklist
recommended by Cochrane Collaboration. Each of the
11 items in the QUADAS checklist was scored as “yes”,
“no”,o r“unclear” [8].
Representative patient spectrum
HCC typically develops in patients with chronic liver dis-
ease and cirrhosis [2]. It is in these target populations that
serum markers are most urgently needed. Patients with
chronic liver disease or cirrhosis who were suspected as
having HCC were scored “yes”. Studies that recruited
healthy patients in the control group and groups known to
have HCC were scored “no”. Studies without sufficient
information to make a judgment were scored “unclear”.
Acceptable reference standard
Histopathology is the currently acceptable reference
standard recommended by EASL for HCC. If histo-
pathology is not available, HCC diagnosis is usually
established by ultrasound, MRI or CT when either of
them shows a nodule with arterial hypervascularization
>2 cm [9]. Studies using the reference standard consist-
ing of the above mentioned standards were scored “yes”.
Studies using neither histopathology nor the above ima-
ging modalities were scored “no”. Studies without suffi-
cient information were scored “unclear”.
Suitable time between reference standard and index test
Blood samples collected before intervention were con-
sidered acceptable, knowing that HCC is unlikely to dis-
appear spontaneously. Therefore, studies in which blood
samples were collected before intervention were scored
“yes”. Studies in which blood samples were collected
after intervention were scored “no”. Studies without suf-
ficient information were scored the study as “unclear”.
Sample verification by reference standard
Studies in which all the patients received GP73 and AFP
tests and whose disease status was confirmed by the
above reference standard were scored “yes”. Studies in
which some patients missed the above reference stan-
dard were scored “no”.
Consistency of reference standard
Studies in which the HCC diagnosis was confirmed by
the same type of reference standard (histopathology or
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Studies in which the HCC diagnosis of some patients
was confirmed by histopathology while that of some
other patients was confirmed by imaging modalities
were scored “no”. Studies without sufficient information
to make a conclusive judgment were scored “unclear”.
Reference standard independent of index test
Studies that did not include GP73 and AFP in the refer-
ence standard were scored “yes”, and studies that
included GP73 and AFP in the reference standard were
scored “no”.
Reference standard blinded
Studies in which blood samples for GP73 and AFP mea-
surement were analyzed by technicians who were blind
to the reference standard results were scored “yes”.S t u -
dies in which blood samples for GP73 and AFP mea-
surement were analyzed by technicians who were aware
of the reference standard results were scored “no”.S t u -
dies without providing sufficient information were
scored “unclear”.
Index test blinded
Studies in which the disease status was confirmed by the
reference standard in all patients without the results of
GP73 and AFP were scored “yes”. Studies with known
GP73 or AFP results were scored “no”.
Relevant clinical information
Studies were scored “yes” in which the same clinical
data were available when test results were interpreted as
would be available when the test is used in practice. Stu-
dies with unavailable clinical data in practice were
scored “no”. Studies without sufficient information were
scored “unclear”.
Uninterpretable/intermediate test results reported
Studies in which all uninterpretable or intermediate results
were reported were scored “yes”. Studies without reporting
intermediate results were scored “no”. Studies without suf-
ficient information to judge were scored “unclear”.
Explained withdrawals
Studies in which all details that happened to the patients
included were clearly reported were scored “yes”. Studies
without explaining the reason for withdrawal were
scored “no”.
Data analysis
Using the ‘metandi’ module for Stata (version 10), sensitiv-
ity and specificity were calculated, and the diagnostic accu-
racy was summarized for each study. Meta-regression was
performed in an attempt to explain the observed
heterogeneity. Data were presented as forest plots and
receiver operating characteristic curves. Forest plots display
the sensitivity and specificity of individual studies with the
corresponding 95% confidence intervals. The receiver oper-
ating characteristic curves show individual study data
points with size proportional to study weight, and the hier-
archical summary curve resulting from the hierarchical
summary receiver operating characteristic model.
Results
A total of 149 articles were found, of which 20 publica-
tions dealing with GP73 for the diagnosis of HCC were
considered to be eligible for inclusion in the analysis.
After full-text review, 12 studies were excluded: five arti-
cles were excluded because they did not allow the calcu-
lation of sensitivity or specificity [10-14]; five articles
were excluded because of lacking AFP test [7,15-18],
and two were excluded because they had a suspected
overlap study population with another study in which
results were most completely reported (Table 1) [19,20].
Finally, 8 studies were available for the meta-analysis,
including 5,988 patients who received both serum GP73
and AFP tests (Figure 1) [21-28]. The characteristics of
each study are shown in Table 2.
Quality of the studies
QUADAS quality assessment of the included studies is
s h o w ni nF i g u r e2 .S u m m a r ys c o r e sw e r en o tc a l c u l a t e d
because their interpretation is problematic and potentially
misleading [29]. However, the quality was not satisfactory.
All studies used a retrospective design, and in three studies
the blood samples were collected from consecutive
patients. Seven studies recruited healthy people in the con-
trol group. The percentage of HCC in these studies ranged
from 18.7% to 59.2%. Six studies reported the diagnostic
standard of HCC, and four reported the tumor stage of
the cancer patients included. Three studies clearly stated
that blood samples were collected before any intervention
but none of the eight studies interpreted serum GP73 test
levels with diagnosis blinded.
The summary diagnostic accuracy of GP73 vs. AFP for
HCC
The sensitivity that these studies observed ranged from
6.7% to 90.9% (summary 76%; 95%CI 51-91%), 30% to
95.2% (summary 70%; 95% CI 47-86%) for GP73 and
AFP levels in the diagnosis of HCC, respectively, while
the specificity ranged from 51.8% to 97.4% (summary
86%; 95%CI 65-95%), 47.1% to 99.1% (summary 89%;
95%CI 69-96%) (Table 3). We also noted that the sum-
mary diagnostic odds ratio (DOR) and the area under
sROC was 18.59 (95%CI 5.33-64.91) and 0.88(95%CI
0.77-0.99) versus 18.00 (95%CI 9.41-34.46) and 0.86(95%
CI 0.84-0.87) for GP73 and AFP respectively. We
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CI of each study in the forest plot, and the significant
heterogeneity was observed (Figure 3).
The SROC approach is the standard method for meta-
analyzing diagnostic reporting pairs of sensitivity and
specificity [30]. It uses DOR as the main outcome mea-
sure which removes the effect of a possible threshold
[ 3 1 ] .S ow ep r e s e n t e dt h es R O Cc u r v e so b t a i n e db y
using the parameters of the hierarchical model to pre-
sent overall summary of GP73 and AFP. As is shown in
Figure 4, the SROC curve of paired data of serum GP73
and AFP indicates that the GP73 curve falls near the
AFP curve. Thus, we conclude that serum GP73 had a
comparable accuracy to AFP as a diagnostic marker for
HCC. Because the threshold level varies from study to
study, we did not estimate the summary points and 95%
confidence region for the two markers.
The diagnostic accuracy of GP73 vs. AFP for early HCC
T h ed i a g n o s t i cv a l u e so fG P73 vs. AFP for detecting
early HCC (TNM I-II) were reported in three studies.
The raw data for the two markers are shown in Figure
3. As the “metandi” command in Stata requires data
from more than four studies, we used the Metadisc
(Version 1.4; Clinical Biostatistics Unit, Ramon y Cajal
Hospital, Madrid, Spain). The pooled sensitivity and spe-
cificity for GP73 were comparable to AFP: sensitivity
79% (95% CI 74-84%) vs. 79% (74-83%) and specificity
62% (95% CI 58-66%) vs. 60% (56-64%). While DOR
turned to be better for AFP than GP73: 11.85 (95% CI
6.92-20.30) vs. 8.03 (95% CI 2.73-23.58).
Meta- regression for heterogeneity
The heterogeneity presented within the studies can be also
observed in the SROC diagram. We attempted to explain
this heterogeneity by exploring the study characteristics
using meta-regression. The accuracy measure used was
DOR, as it is a unitary measure of diagnostic performance
that encompasses both sensitivity and specificity or both
LR positive and LR negative. But limited by the small
number of studies, we found that the differences for preva-
lence of HCC, cut-off value, consecutive patient recruit-
ment, and assay methods used for markers did not have a
statistically significant effect on DOR (Table 4).
Discussion
We found and assessed eight studies that directly com-
pared the diagnostic accuracy of serum GP73 and AFP
Table 1 Characteristics of the excluded studies
study Reason for exclusion
Block 2005 Patients: HCC vs. Healthy
Tests: immunoblot assay for GP73, AFP not measured.
Outcomes: no usable data.
Mao 2008 Suspected overlapped study population with Mao 2010
Chen 2011 Suspected overlapped study population with Mao 2010.
Li 2009a Patients: HCC vs. cholangiocellular carcinoma
Tests: GP73, AFP and VEGF expression in tumor, tumor-
adjacent and normal liver specimens by
immunohistochemistry.
Outcomes: no usable data.
Riener 2009a Patients: HCC vs. (healthy and viral hepatitis)
Tests: methods for GP73and AFP test not cleared
reported
Outcomes: no usable data.
Riener 2009b Patients: HCC vs. (chronic HCV infection, bile duct
carcinoma and healthy)
Test: sera GOLPH2 detection using ELISA, AFP not tested.
Outcomes: no usable data.
Stenner 2009 Patients: HCC vs. (HCV, bile duct carcinoma and healthy)
Tests: sera GOLPH2 levels by ELISA, unclear whether AFP
tested or not.
Abstract; no clear data reported.
Li 2009b Patients: HCC vs. (cirrhosis and healthy)
Tests: methods for serum GOLPH2 and AFP not reported.
Letter; no usable data.
Yamamoto
2009
Patients: HCC
Tests: serum GP73 autoantigen/autoantibody and AFP
measured
Abstract, no usable data.
Yamamoto
2010
Patients: HCC
Tests: serum GP 73 autoantigen and autoantibody
measured by ELISA.
Outcomes: sensitivity/specificity at cutoff points was not
calculated.
Tan 2009 Patients: HCC vs. (liver disease without HCC and healthy)
Tests: serum GOLPH2 levels by ELISA, AFP not measured.
Outcomes: sensitivity, specificity and cut off value were
available, but AFP levels were not tested.
Gu 2009 Patients: HCC vs. cirrhosis
Tests: GP73 by ELISA, AFP not tested.
Outcomes: sensitivity, specificity and cut off value were
available, but AFP levels were not tested.
Figure 1 Flow diagram indicating the process of selecting
articles for meta-analysis.
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t h a tG P 7 3i sac o m p a r a b l em a r k e rf o rH C Ct oA F P .
However, the studies showed numerous methodological
limitations, a broad range of diagnostic accuracy values
and heterogeneity. The methodological quality of the
eight studies is poor, and one of the studies did not
even report the age and sex of the patients included.
Five of the studies stated that serum GP73 was advanta-
geous over AFP, while the remaining three studies
reported opposite results. Because of the limited number
and the different cutoff values of the studies included in
this meta-analysis, we were not able to explore causes
for the existing big heterogeneity by meta-regression.
The increasing incidence of HCC worldwide has
sparked a new interest in HCC serum markers. A num-
ber of novel candidate markers have been suggested.
GP73 is a 400-amino acid 73-kDa transmembrane glyco-
protein that normally resides in epithelial cells of many
human tissues [32]. Higher levels of serum GP73 were
first found in patients with hepatitis B virus-related
HCC by Block in 2005 [7]. Although the precise
mechanism of GP73 elevation in the circulation remains
obscure, serum GP73 has gained great interest for its
potent role in the diagnosis of HCC. Western blotting,
immunoblotting and ELISA are three major methods
used to assay GP73. The former two are semiquantita-
tive and laborious, but the results of ELISA are disap-
pointing. Six studies [18,21,23,24,27,33] using ELISA
method failed to find significant elevation of serum
GP73 in HCC groups compared with that in liver cir-
rhosis groups. Recently described GP73-specific serum
autoantibodies might interfere with ELISA analysis.
Researchers have found several isoforms of GP73 that
correspond with different patterns or levels of glycosyla-
tion [34]. Whether measuring HCC-specific GP73 iso-
form helps improve the diagnostic accuracy still needs
further research.
The goal of cancer-screening is to detect tumors at an
early stage when successful treatment is possible [35].
An ideal biomarker should be specific and noninvasive.
The field of HCC serum markers is primed for new can-
didate markers that have the potential to replace their
flawed leader AFP [36]. To avoid substantial
Table 2 Characteristics of included studies
study country HCC/controls tumor staging (TNM) GP 73 AFP
assay type cutoff value assay type cutoff value
Hu2009 China 31/93 NK
b westernblot 7.4 RU
a ELISA 36 ug/L
Morota2011 USA 70/156 NK ELISA 94.7 ug/L ELISA 15.3 ug/L
Ozkan2010 Turkey 75/83 3/20/14/38 ELISA 2.36 ug/L ELISA 4.36 ug/L
Mao2010 China, USA 789/3428 NK immunoblot 8.5 RU ELISA 35 ug/L
Marrero2005 USA 144/108 17/52/59/16 immunoblot 10 RU ELISA 99 ug/L
Tian2010 China 153/219 23/95/30/5 ELISA 113.8 ug/L ELISA 13.6 ug/L
Wang2009 USA 164/113 38/70/34/22 immunoblot NK ELISA NK
Shi2011 China 55/107 NK ELISA 100 ug/L ELISA 400 ug/L
a Relative Unit; b Not Known
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Figure 2 Summary of methodological quality of included
studies on the basis of review authors’ judgments on the 11
items of QUADAS checklist for each study.
Table 3 Summary of diagnostic accuracy of GP73 and
AFP using “metandi” module in stata10
summary GP73 AFP
Coef. Std. err 95% CI Coef. std err 95% CI
sensitivity 0.76 0.10 0.51-0.91 0.70 0.10 0.47-0.86
specificity 0.86 0.07 0.65-0.95 0.89 0.06 0.69-0.96
DOR 18.59 11.86 5.33-64.91 18.00 5.96 9.41-34.46
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Page 5 of 8confounding factors in comparisons, we only used stu-
dies that directly compared GP73 with AFP in the same
patients. However, fully paired studies are usually scant.
Despite the big heterogeneity, we still found that GP73
m a yb eac o m p a r a b l em a r k e rt oA F Pf o rH C C .H o w -
ever, cancer is a diverse class of diseases that differ
widely in their causes and biology, and therefore it is
unlikely for a single biomarker to detect all cancers of a
particular organ with high specificity and sensitivity.
The diagnostic value of GP73 combined with AFP for
HCC was stated in Wang’sa n dM a o ’sr e p o r t s ,a n dt h e
results seem better than the single marker. However,
further observation is needed in more studies.
Only three studies reported diagnostic utility of serum
GP73 compared AFP by tumor stage and the conclu-
sions were conflicting. The diagnostic ability of GP73 to
detect HCC in an early stage needs further observation.
One of the major goals of meta-analysis is to explore
reasons for heterogeneity rather than computation of a
single summary measure [37]. Notably, the differential
cutoff values within the studies could cause a threshold
effect. Different study populations appeared to have sub-
stantially influenced the diagnostic sensitivity [38]. In
our meta-analysis, the prevalence of HCC, cutoff value,
consecutive patient selection and assay method were
used in the meta-regression analysis to assess the effect
of study methodology and threshold on DOR. Because
of the small number of studies included, we used the
permutation test recommended by Higgins and Thomp-
son [39]. But we failed to find the reason responsible for
the existing heterogeneity. The following reasons may
hamper the statistical analysis of sources of heterogene-
ity: First, many reports of studies on diagnostic accuracy
lacked information on key elements of design and con-
duct. Without complete and accurate reporting, we can-
not correctly identify potential sources of bias and
variability. Second, few studies using direct comparisons
are available. The small numbers also made subgroup
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Figure 3 Forest plot of pairs of sensitivity and specificity in each study included. TP = true positive; FP = false positive; FN = false
negative; TN = true negative. Forest plots document the extracted data for each study together with estimates of sensitivity and specificity
accompanied by 95% CIs.
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Page 6 of 8analysis unavailable. Third, the diagnostic meta-analysis
is also threatened by publication bias. Investigating pub-
lication bias for diagnostic tests is problematic. Funnel
plot-based tests used to detect publication bias in review
of randomized controlled trials have proven to be ser-
iously misleading for diagnostic studies, and alternatives
have poor power [40].
Conclusions
In conclusion, our meta-analysis found that GP73 is a
comparable marker to AFP as an independent diagnostic
tool for the diagnosis of HCC. The combination value of
GP73 and AFP still needs further research. The cur-
rently existing studies on GP73 have not yet met the
most stringent criteria defined by the Early Detection
Research Network. Future studies should be designed to
prospectively test markers in appropriately selected risk
populations.
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